CASI Pharmaceuticals Inc. (CASI)
2.00
0.02 (1.01%)
At close: Apr 23, 2025, 3:46 PM
2.17
8.32%
Pre-market: Apr 24, 2025, 08:10 AM EDT
1.01% (1D)
| Bid | 1.93 |
| Market Cap | 26.8M |
| Revenue (ttm) | 28.54M |
| Net Income (ttm) | -39.26M |
| EPS (ttm) | -2.56 |
| PE Ratio (ttm) | -0.78 |
| Forward PE | -1.13 |
| Analyst | Buy |
| Ask | 2.44 |
| Volume | 3,476 |
| Avg. Volume (20D) | 12,259 |
| Open | 1.97 |
| Previous Close | 1.98 |
| Day's Range | 1.97 - 2.00 |
| 52-Week Range | 1.88 - 7.67 |
| Beta | 0.61 |
About CASI
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T inve...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 1996
Employees 233
Stock Exchange NASDAQ
Ticker Symbol CASI
Analyst Forecast
According to 1 analyst ratings, the average rating for CASI stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 100.00% from the latest price.
Stock ForecastsNext Earnings Release
CASI Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+0.95%
CASI Pharmaceuticals shares are trading higher aft...
Unlock content with
Pro Subscription
10 months ago
+36.49%
CASI Pharmaceuticals shares are trading higher after the company announced plans to submit an Investigational New Drug application to the FDA for CID-103 for the treatment of antibody-mediated rejection in kidney transplant recipients. Also, the company received a preliminary non-binding proposal letter from CEO and Chairman Wei-Wu He to acquire its business operations in China.
